Privium Fund Management B.V. Sells 16,600 Shares of Moderna, Inc. (NASDAQ:MRNA)

Privium Fund Management B.V. decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 41.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 23,261 shares of the company’s stock after selling 16,600 shares during the quarter. Moderna comprises approximately 0.7% of Privium Fund Management B.V.’s portfolio, making the stock its 29th largest holding. Privium Fund Management B.V.’s holdings in Moderna were worth $2,723,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the 4th quarter worth $27,000. Cedar Wealth Management LLC grew its position in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Westside Investment Management Inc. bought a new position in Moderna during the first quarter valued at about $32,000. Family Firm Inc. bought a new position in Moderna during the second quarter valued at about $33,000. Finally, Rise Advisors LLC grew its position in Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 0.2 %

Shares of Moderna stock traded down $0.19 on Friday, reaching $77.40. The stock had a trading volume of 3,591,705 shares, compared to its average volume of 4,084,163. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $104.62 and its two-hundred day moving average is $112.99.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($3.62) earnings per share. Equities analysts expect that Moderna, Inc. will post -9.52 EPS for the current year.

Insider Buying and Selling

In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the transaction, the president now directly owns 1,457,089 shares in the company, valued at $201,311,416.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the transaction, the president now directly owns 1,457,089 shares in the company, valued at $201,311,416.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO James M. Mock sold 689 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 330,736 shares of company stock worth $46,330,112. Insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MRNA shares. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday. Oppenheimer increased their price target on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. UBS Group increased their price target on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. Ten investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $123.79.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.